Clinical peculiarities of antibiotic associated bowels impairment and its significance in irritable bowel syndrome appearance
DOI:
https://doi.org/10.14739/2310-1210.2016.3.76983Keywords:
Bowel, Irritable Bowel Syndrome, Antibiotics, TherapyAbstract
Aim: the main objective of this study was to investigate bowels impairment due to treatment with antibiotics, its incidence and clinical peculiarities; to evaluate its role in appearance of in irritable bowel syndrome.
Material and Methods. We studied 110 patients (33 males and 77 females), age range 16-83 years, who received treatment with antibiotic. We evaluated the function of the intestine before treatment with antibiotic, then in 1 week, 3 months after treatment finish (1, 2, 3, 4 visits respectively). Control group included 20 healthy persons, who haven't had antibiotics administered during recent two years.
Results. We revealed that the signs of bowel function impairment took place at the first visit in 18.2% of patients, at the second visit – in 60.0% of patients, at the third visit – in 45.5% of patients and at the fourth visit – in 41.1% of patients. At the second, third and fourth visits the signs of bowels function impairment were observed reliably more often then at the first visit (before antibiotic administration), p<0.001). At the second visit the signs bowels function disorders were the most prominent: abdominal pain – in 44.5%, distention – in 46.4%, diarrhea – in 29.1%, constipation – in 18.2%, presence of both (diarrhea and periodically constipation) manifestations – in 2.7%; and extraintestinal manifestations (depression. depressed mood, sorrow, apathy, decreased stamina, sleep disturbances – in 29.1% of patients. Clinical manifestations of irritable bowel syndrome occured in 6 months of observation in 32.2% of patients.
Conclusions. The signs of bowel function impairment were observed in 60.0% of patients after finishing treatment with antibiotic. This incidence is much higher than in control group (р<0.001). Bowel disorders mostly manifested as the changes in quantity and consistency of feaces, pain, abdominal distention and extraintestinal manifestations. In 32.2% of patients clinical manifestations of irritable bowel syndrome developed in 6 months of observation. This incidence is reliably higher than before treatment (10.9% of patients) and compared with control group (5.0% of patients), of observation р<0.01.
References
Dorofeev, A. E., Rudenko, N. N., Konovalova-Kushnуr, T. А., & Derkach, I. A. (2016). Rol' rifaksimina v lechenii postinfekcionnogo sindroma razdrazhennoj kishki [The role of rifaximin in the treatment of postinfectious irritable bowel syndrome]. Suchasna hastroenterolohiia, 1(87), 105–109. [in Ukrainian].
Weinberg, D. S., Smalley, W., Heidelbaugh, J. J. & Sultan, S. (2014). American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology, 147, 1146–1148. doi: 10.1053/j.gastro.2014.09.001.
Vdovychenko, V. I., Korniichuk, O. P., Bychkov, M. A., Merentsova, О. О., Pasichna, I. О., & Nahurna, Ya. V. (2014) Syndrom podraznenoi kyshky: navchalnyi posibnyk [Irritable bowel syndrome: tutorial]. Lviv: SPOLOM. [in Ukrainian].
Villarreal, A. А., Aberger, F. J., Benrud, R., & Gundrum, J. D. (2012) Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ; 111(1), 17–20.
Barbara, G. (2011) Toll-like receptor expression in irritable bowel syndrome: on the alert for a microbial threat? Am J Gastroenterol, 106, 337–339. doi: 10.1038/ajg.2010.440.
Solomenceva, T. A. (2016). Sindrom razdrazhennogo kishechnika. Trudnosti v diagnostike i lechenii [Irritable bowel syndrome: the difficulties in diagnosis and treatment]. Suchasna hastroenterolohiia, 2(88), 114–120. [in Ukrainian].
Kharchenko, N. V. (2014) Optymalni pidkhody do likuvannia boliu pry syndromi podraznenoho kyshechnyka [Optimal approaches for pain relief in patients with irritable bowel syndrome]. Suchasna hastroenterolohiia, 3(77), 43–48. [in Ukrainian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
